Skip to main content

Welkom bij THIM Hogeschool voor Fysiotherapie & Bohn Stafleu van Loghum

THIM Hogeschool voor Fysiotherapie heeft ervoor gezorgd dat je Mijn BSL eenvoudig en snel kunt raadplegen. Je kunt je links eenvoudig registreren. Met deze gegevens kun je thuis, of waar ook ter wereld toegang krijgen tot Mijn BSL. Heb je een vraag, neem dan contact op met helpdesk@thim.nl.

Registreer

Om ook buiten de locaties van THIM, thuis bijvoorbeeld, van Mijn BSL gebruik te kunnen maken, moet je jezelf eenmalig registreren. Dit kan alleen vanaf een computer op een van de locaties van THIM.

Eenmaal geregistreerd kun je thuis of waar ook ter wereld onbeperkt toegang krijgen tot Mijn BSL.

Login

Als u al geregistreerd bent, hoeft u alleen maar in te loggen om onbeperkt toegang te krijgen tot Mijn BSL.

Top
Gepubliceerd in:

01-05-2010 | Editorial

Safety of dual antiplatelet therapy in daily cardiology practice

Auteur: F. W. A. Verheugt

Gepubliceerd in: Netherlands Heart Journal | Uitgave 5/2010

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Extract

Dual antiplatelet therapy has become the cornerstone of the treatment of acute coronary syndromes with or without stent implantation.1 Although there is consensus about the indication for dual antiplatelet therapy, there is little evidence about the optimal duration of therapy. In patients surviving non-ST-segment-elevation acute coronary syndromes one year of treatment is advised.2 Intuitively, cardiologists prefer longer dual antiplatelet therapy rather than single antiplatelet medication (aspirin alone) in patients with drug-eluting stents when compared with carriers of bare metal stents. Consequently, many patients in the cardiology practice in 2010 are on dual antiplatelet therapy, mainly aspirin and clopidogrel. The only important side effect of dual antiplatelet therapy is increased bleeding in comparison with aspirin alone. This has been established in the large trials with clopidogrel in acute coronary syndromes3,4 as well as in atrial fibrillation.5 Especially in de latter dual antiplatelet therapy has shown to be as hazardous as oral anticoagulation.6 Special attention has been given to the risks of dual antiplatelet therapy in patients awaiting coronary artery bypass surgery. Clopidogrel on top of aspirin has been associated with significantly increased blood loss during coronary surgery when compared with aspirin alone.7 However, this excess bleeding was not significantly associated with an increased risk of reoperation or mortality. Yet, it is generally advised to discontinue clopidogrel five days ahead of coronary surgery. Little is known, however, about the optimal strategy in patients on dual antiplatelet therapy undergoing other forms of surgery such as abdominal surgery, orthopaedic procedures, neurosurgical operations or procedures in other vital organs where bleeding can result in organ loss. Recently, the first guideline on interruption of antiplatelet therapy in general and of dual antiplatelet therapy in particular was published.8 In that guideline, patients with high, medium and low thrombotic risk are identified. In patients with the highest thrombotic risk antiplatelet therapy should be continued, and in the patient with a low thrombotic risk this can be discontinued prior to surgery. …
Literatuur
1.
go back to reference Van de Werf F. New antithrombotic agents: are they needed and what can they offer to patients with a non-ST-elevation acute coronary syndrome? Eur Heart J. 2009;30:1695-702. Van de Werf F. New antithrombotic agents: are they needed and what can they offer to patients with a non-ST-elevation acute coronary syndrome? Eur Heart J. 2009;30:1695-702.
2.
go back to reference Bassand JP, Hamm CW, Ardissino D, et al. Guidelines for the diagnosis and treatment of non ST-elevation acute coronary syndromes. Eur Heart J. 2007;28:1598-660. Bassand JP, Hamm CW, Ardissino D, et al. Guidelines for the diagnosis and treatment of non ST-elevation acute coronary syndromes. Eur Heart J. 2007;28:1598-660.
3.
go back to reference CURE Investigators. Effect of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494-502. CURE Investigators. Effect of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494-502.
4.
go back to reference COMMIT(Clopidogrel and Metoprolol in Myocardial Infarction Trial) Collaborative Group. Addition of clopidogrel to aspirin in 45852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005;366:1607-2. COMMIT(Clopidogrel and Metoprolol in Myocardial Infarction Trial) Collaborative Group. Addition of clopidogrel to aspirin in 45852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005;366:1607-2.
5.
go back to reference ACTIVE Investigators. Effect of clopidogrel added to aspirin in atrial fibrillation. N Engl J Med. 2009;360;1266-78. ACTIVE Investigators. Effect of clopidogrel added to aspirin in atrial fibrillation. N Engl J Med. 2009;360;1266-78.
6.
go back to reference Verheugt FWA. Good old warfarin for stroke prevention in atrial fibrillation. Lancet. 2006;367:1877-8. Verheugt FWA. Good old warfarin for stroke prevention in atrial fibrillation. Lancet. 2006;367:1877-8.
7.
go back to reference Fox KAA, Mehta SR, Peters R, et al. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) trial. Circulation. 2004;110:1202-8. Fox KAA, Mehta SR, Peters R, et al. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) trial. Circulation. 2004;110:1202-8.
8.
go back to reference Douketis JD, Berger PB, Dunn AS, et al. Perioperative management of antithrombotic therapy: American College of Chest Physician evidence-based clinical practice guidelines (8th edition). Chest. 2009;133(Suppl 6):299S-339S. Douketis JD, Berger PB, Dunn AS, et al. Perioperative management of antithrombotic therapy: American College of Chest Physician evidence-based clinical practice guidelines (8th edition). Chest. 2009;133(Suppl 6):299S-339S.
9.
go back to reference Przybylski A, Derejko P, Kwasniewski W, Urbańczyk-Świć D, Zakrzewska J, Orszulak W, et al. Bleeding complications after pacemaker or cardioverter-defibrillator implantation in patients receiving dual antiplatelet therapy: the results of a prospective, two-centre registry. Neth Heart J. 2010;18:230-235. Przybylski A, Derejko P, Kwasniewski W, Urbańczyk-Świć D, Zakrzewska J, Orszulak W, et al. Bleeding complications after pacemaker or cardioverter-defibrillator implantation in patients receiving dual antiplatelet therapy: the results of a prospective, two-centre registry. Neth Heart J. 2010;18:230-235.
10.
go back to reference Collet JP, Montalescot G, Blanchet B, et al. Impact of prior use of recent withdrawal of oral antiplatelet agents on acute coronary syndromes. Circulation. 2004;110:2361-7. Collet JP, Montalescot G, Blanchet B, et al. Impact of prior use of recent withdrawal of oral antiplatelet agents on acute coronary syndromes. Circulation. 2004;110:2361-7.
11.
go back to reference Van Werkum JW, Heestermans AA, Zomer AC, Kelder JC, Suttorp MJ, Rensing BJ, et a. Predictors of coronary stent thrombosis: the Dutch Stent Thrombosis Registry. J Am Coll Cardiol. 2009;53:1399-409. Van Werkum JW, Heestermans AA, Zomer AC, Kelder JC, Suttorp MJ, Rensing BJ, et a. Predictors of coronary stent thrombosis: the Dutch Stent Thrombosis Registry. J Am Coll Cardiol. 2009;53:1399-409.
12.
go back to reference Ferrari E, Benhamou M, Cerboni P, Marcel B. Coronary syndromes following aspirin withdrawal: a special risk for late stent thrombosis. J Am Coll Cardiol. 2005;45:456-9. Ferrari E, Benhamou M, Cerboni P, Marcel B. Coronary syndromes following aspirin withdrawal: a special risk for late stent thrombosis. J Am Coll Cardiol. 2005;45:456-9.
13.
go back to reference Maulaz AB, Bezerra DC, Michel P, Bogousslavsky J. Effect of discontinuing aspirin therapy on the risk of brain ischemic Stroke. Arch Neurol. 2005;62:1217-20. Maulaz AB, Bezerra DC, Michel P, Bogousslavsky J. Effect of discontinuing aspirin therapy on the risk of brain ischemic Stroke. Arch Neurol. 2005;62:1217-20.
14.
go back to reference Ruiz-Nodar JM, Marin F, Hurtado JF, et al. Anticoagulant and antiplatelet therapy use in 426 patients with atrial fibrillation undergoing percutaneous coronary intervention and stent implantation: implications for bleeding risk and prognosis. J Am Coll Cardiol. 2008;51:818-25. Ruiz-Nodar JM, Marin F, Hurtado JF, et al. Anticoagulant and antiplatelet therapy use in 426 patients with atrial fibrillation undergoing percutaneous coronary intervention and stent implantation: implications for bleeding risk and prognosis. J Am Coll Cardiol. 2008;51:818-25.
15.
go back to reference Dewilde W, Ten Berg JM. Design and rationale of the WOEST trial: what is the optimal antiplatelet and anticoagulant therapy in patients with oral anticoagulation and coronary stenting. Am Heart J. 2009;158:713-8. Dewilde W, Ten Berg JM. Design and rationale of the WOEST trial: what is the optimal antiplatelet and anticoagulant therapy in patients with oral anticoagulation and coronary stenting. Am Heart J. 2009;158:713-8.
Metagegevens
Titel
Safety of dual antiplatelet therapy in daily cardiology practice
Auteur
F. W. A. Verheugt
Publicatiedatum
01-05-2010
Uitgeverij
Bohn Stafleu van Loghum
Gepubliceerd in
Netherlands Heart Journal / Uitgave 5/2010
Print ISSN: 1568-5888
Elektronisch ISSN: 1876-6250
DOI
https://doi.org/10.1007/BF03091767